Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.40 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.40 |
| ▸ | CHRNB4 | P30926 | 2/20 | 0.39 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.39 |
| ▸ | TGM2 | P21980 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14915852 | 1.00 | POLB (0.48) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL30512278 | 0.85 | MAPT (0.52) | POLBMAPTRAB9ASMN1; SMN2TGM2 | |
| SCHEMBL14925978 | 0.85 | MAPT (0.52) | POLBMAPTRAB9ASMN1; SMN2TGM2 | |
| SCHEMBL16824828 | 0.82 | AKR1C3 (0.49) | POLBMAPTSMN1; SMN2LMNAAKR1C3 | |
| SCHEMBL29742102 | 0.81 | MAPT (0.42) | POLBMAPTRAB9ASMN1; SMN2TGM2 | |
| SCHEMBL14915312 | 0.80 | TRPC6 (0.39) | SMN1; SMN2CHRNB2CHRNA4 | |
| SCHEMBL1393988 | 0.78 | MAPT (0.67) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL1393989 | 0.78 | MAPT (0.67) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| SCHEMBL27676282 | 0.76 | MAPT (0.53) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 | |
| Ammonia Solution, Strong SCHEMBL21245872 | 0.75 | MAPT (0.58) | POLBMAPTRAB9ASMN1; SMN2CHRNB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2773639-B1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | HOFFMANN LA ROCHE (CH) | 2017-04-26 | — | — | EP | disclosed |
| US-9115152-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-08-25 | — | — | US | disclosed |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2015-04-02 | — | — | US | disclosed |
| US-8946213-B2 | Alkylated piperazine compounds | GENENTECH, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2773639-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-10 | — | — | EP | disclosed |
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2014-08-07 | — | — | US | disclosed |
| US-8729072-B2 | Alkylated piperazine compounds | F. HOFFMAN-LA ROCHE AG (CH) | 2014-05-20 | — | — | US | disclosed |
| WO-2013067277-A1 | ALKYLATED PIPERAZINE COMPOUNDS AS INHIBITORS OF BTK ACTIVITY | GENENTECH, INC. (US) | 2013-05-10 | — | — | WO | disclosed |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | GENENTECH, INC. (US) | 2013-05-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221365-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | POLB 1560/4885MAPT 2501/4885RAB9A 3047/4885 |
| US-20130116245-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | POLB 1481/4885MAPT 1919/4885RAB9A 3385/4885 |
| US-20150094302-A1 | ALKYLATED PIPERAZINE COMPOUNDS | BTK, SYK, LCK | POLB 1560/4885MAPT 2501/4885RAB9A 3047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.